| Literature DB >> 31446001 |
Mario Sa1, Rinki Singh2, Suresh Pujar1, Felice D'Arco3, Nivedita Desai1, Christin Eltze1, Elaine Hughes4, Muthana Al Obaidi5, Despina Eleftheriou6, Martin Tisdall7, Richard Selway8, J Helen Cross9, Marios Kaliakatsos10, Antonio Valentin2.
Abstract
Febrile infection-related epilepsy syndrome (FIRES) is a severe epilepsy disorder that affects previously healthy children. It carries high likelihood of unfavourable outcome and putative aetiology relates to an auto-inflammatory process. Standard antiepileptic drug therapies including intravenous anaesthetic agents are largely ineffective in controlling status epilepticus in FIRES. Deep brain stimulation of the centromedian thalamic nuclei (CMN-DBS) has been previously used in refractory status epilepticus in only a few cases. The use of Anakinra (a recombinant version of the human interleukin-1 receptor antagonist) has been reported in one case with FIRES with good outcome. Here we describe two male paediatric patients with FIRES unresponsive to multiple anti-epileptic drugs, first-line immune modulation, ketogenic diet and cannabidiol. They both received Anakinra and underwent CMN-DBS. The primary aim for CMN-DBS therapy was to reduce generalized seizures. CMN-DBS abolished generalized seizures in both cases and Anakinra had a positive effect in one. This patient had a favourable outcome whereas the other did not. These are the first reported cases of FIRES where CMN-DBS has been used. CrownEntities:
Keywords: Anakinra; Centromedian thalamic nuclei; Deep brain stimulation; FIRES
Mesh:
Substances:
Year: 2019 PMID: 31446001 DOI: 10.1016/j.ejpn.2019.08.001
Source DB: PubMed Journal: Eur J Paediatr Neurol ISSN: 1090-3798 Impact factor: 3.140